Orgenesis (ORGS) Competitors $0.06 +0.04 (+177.27%) As of 08/7/2025 11:50 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGS vs. ENTO, VCNX, WINT, ADTX, SXTP, APVO, GRTX, SHPH, ONCO, and PTIXShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Entero Therapeutics (ENTO), Vaccinex (VCNX), Windtree Therapeutics (WINT), Aditxt (ADTX), 60 Degrees Pharmaceuticals (SXTP), Aptevo Therapeutics (APVO), Galera Therapeutics (GRTX), Shuttle Pharmaceuticals (SHPH), Onconetix (ONCO), and Atrinsic (PTIX). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Its Competitors Entero Therapeutics Vaccinex Windtree Therapeutics Aditxt 60 Degrees Pharmaceuticals Aptevo Therapeutics Galera Therapeutics Shuttle Pharmaceuticals Onconetix Atrinsic Orgenesis (NASDAQ:ORGS) and Entero Therapeutics (NASDAQ:ENTO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership. Does the media favor ORGS or ENTO? In the previous week, Entero Therapeutics had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for Entero Therapeutics and 0 mentions for Orgenesis. Orgenesis' average media sentiment score of 0.00 beat Entero Therapeutics' score of -1.00 indicating that Orgenesis is being referred to more favorably in the media. Company Overall Sentiment Orgenesis Neutral Entero Therapeutics Negative Which has more volatility & risk, ORGS or ENTO? Orgenesis has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Comparatively, Entero Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Is ORGS or ENTO more profitable? Entero Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Orgenesis-3,827.81% N/A -130.18% Entero Therapeutics N/A -1,063.82%-26.06% Do institutionals & insiders have more ownership in ORGS or ENTO? 22.6% of Orgenesis shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 5.7% of Orgenesis shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher earnings & valuation, ORGS or ENTO? Entero Therapeutics has lower revenue, but higher earnings than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrgenesis$662K0.44-$55.36MN/AN/AEntero TherapeuticsN/AN/A-$18.06MN/AN/A SummaryOrgenesis and Entero Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$293K$790.98M$5.44B$9.65BDividend YieldN/A4.84%3.99%4.14%P/E RatioN/A1.3230.0425.06Price / Sales0.4424.96373.4277.08Price / CashN/A19.5635.9458.58Price / Book-0.016.558.125.67Net Income-$55.36M-$4.07M$3.25B$265.39M7 Day PerformanceN/A-0.87%0.96%2.54%1 Month PerformanceN/A2.67%2.69%1.89%1 Year PerformanceN/A24.62%28.08%24.09% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesis1.2236 of 5 stars$0.06+177.3%N/AN/A$293K$662K0.00150Gap DownENTOEntero TherapeuticsN/A$0.44+2.6%N/A-37.6%$2.09MN/A0.009Negative NewsVCNXVaccinexN/A$0.79-3.7%N/A-85.2%$2.05M$388K-0.0240Upcoming EarningsGap DownWINTWindtree Therapeutics1.9539 of 5 stars$0.55-4.8%$350.00+63,076.9%-99.9%$2.02MN/A0.0030ADTXAditxtN/A$0.94-4.7%N/A-100.0%$2.00M$130K0.0060SXTP60 Degrees Pharmaceuticals2.1169 of 5 stars$1.33-0.7%$7.00+426.3%+181.2%$1.96M$665.45K-0.033Upcoming EarningsAPVOAptevo Therapeutics1.8716 of 5 stars$2.55-1.5%$219,040.00+8,589,703.9%-100.0%$1.93M$3.11M0.0050News CoverageGRTXGalera TherapeuticsN/A$0.02-2.2%N/A-78.5%$1.70MN/A-0.0630Upcoming EarningsSHPHShuttle Pharmaceuticals0.8033 of 5 stars$3.70+1.8%N/AN/A$1.63MN/A-0.895Negative NewsONCOOnconetix0.1753 of 5 stars$3.06-3.6%N/A-99.4%$1.61M$2.52M0.0012PTIXAtrinsic0.5708 of 5 stars$2.65-1.5%N/A-67.0%$1.56MN/A-0.202Upcoming Earnings Related Companies and Tools Related Companies Entero Therapeutics Alternatives Vaccinex Alternatives Windtree Therapeutics Alternatives Aditxt Alternatives 60 Degrees Pharmaceuticals Alternatives Aptevo Therapeutics Alternatives Galera Therapeutics Alternatives Shuttle Pharmaceuticals Alternatives Onconetix Alternatives Atrinsic Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGS Stock Alerts